Infinity to raise $77m from stock offer in wake of layoffs
This article was originally published in Scrip
Infinity Pharmaceuticals priced a 5.3 million-share common stock offering at $14.50 per share on 9 August for gross proceeds of $76.9 million to fund research and development for its two lead product candidates and other expenses two days after it announced a 20% work force reduction at its Cambridge, Massachusetts headquarters (scripintelligence.com, 9 August 2012).
You may also be interested in...
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.